Brief: Werewolf Therapeutics Presents Preliminary Monotherapy Data From Phase 1/1b Clinical Trial

Werewolf Therapeutics

03/11/2023 11:06

Nov 3 (Reuters) - Werewolf Therapeutics Inc  HOWL.O :
    * WEREWOLF THERAPEUTICS PRESENTS PRELIMINARY MONOTHERAPY
DATA FROM
PHASE 1/1B CLINICAL TRIAL ESTABLISHING PROOF OF MECHANISM FOR
WTX-124 AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER’S (SITC) 38TH
ANNUAL MEETING
    * WEREWOLF THERAPEUTICS INC - SAFETY DATA INDICATE WTX-124
IS
GENERALLY WELL-TOLERATED THROUGH COHORT 4 WITH NO DOSE LIMITING
TOXICITIES
    * WEREWOLF THERAPEUTICS INC - OPENING OF MONOTHERAPY
EXPANSION
ARMS EXPECTED IN FIRST HALF OF 2024

Source text for Eikon:  ID:nGNX56Vc07 
Further company coverage:  HOWL.O 

 ((Reuters.Briefs@thomsonreuters.com;))